Inhibitory mechanisms of glycoprotein fraction derived from Miscanthus sinensis for the immediate phase response of an IgE-mediated cutaneous reaction.
We investigated the inhibitory effect of the glycoprotein fraction (fraction 2) extracted from Miscanthus sinensi ANDERSSON (M. sinensis) on biphasic cutaneous reactions in mice passively sensitized with IgE. Biphasic skin reactions with peak responses at 1 (IPR, immediate phase reaction) and 24 h (LPR, late phase reaction) were caused by passive sensitization with an anti-dinitrophenol IgE monoclonal antibody (anti-DNP IgE mAb) followed by an epicutaneous challenge of 0.1% dinitrofluorobenzene (DNFB) in 100% ethanol. Intraperitoneal injection of fraction 2 before the DNFB challenge significantly inhibited the biphasic ear swelling response in passively sensitized mice in a dose-dependent manner (1-30 mg/kg). We also found that fraction 2 was effective at inhibiting the vascular permeability in mouse ear induced by an injection of compound 48/80, histamine or serotonin. In addition, fraction 2 inhibited scratching behavior as well as ear edema observed within 2 h after DNFB challenge. Marked inhibition was observed in both passively sensitized and non-sensitized mice. The locomotor activity of mice was also reduced by the administration of fraction 2 as well as by diphenhydramine. These results suggest that the inhibitory effect of glycoprotein fraction 2 of M. sinensis on an IgE-mediated allergic inflammatory reaction is due to the protection of mediator-induced vascular permeability and that in addition to the inhibition of an inflammatory reaction, a sedative action is responsible for the inhibition of allergy-induced scratching responses.
Watanabe
C
C
Department of Pathogenic Biochemistry, Research Institute for Wakan-Yaku, Toyama, Japan.
Satoh
T
T
Tahara
E
E
Murakami
K
K
Hayashi
K
K
Hase
K
K
Andoh
T
T
Kuraishi
Y
Y
Kadota
S
S
Nagai
H
H
Saiki
I
I
D000210:Acute-Phase Reaction / Q000276:immunology / Q000473:pathology*; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects; D003876:Dermatitis, Atopic / Q000276:immunology / Q000473:pathology*; D004139:Dinitrofluorobenzene / Q000276:immunology; D005260:Female; D006023:Glycoproteins / Q000302:isolation & purification / Q000494:pharmacology*; D007073:Immunoglobulin E / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009043:Motor Activity / Q000187:drug effects; D011537:Pruritus / Q000276:immunology / Q000473:pathology; D003313:Zea mays / Q000737:chemistry*